Recommendations For Better Patient Outcomes in LDL-C Management - European Medical Journal

Recommendations For Better Patient Outcomes in LDL-C Management

The EMJ Podcast | Bonus Episode

This EMJ podcast explores the vital topic of low-density lipoprotein cholesterol (LDL-C) management in relation to the treatment and prevention of atherosclerotic cardiovascular disease. Our host, George Cooper, is joined by Michal Vrablík, First Faculty of Medicine, Charles University, Prague, Czech Republic.

Vrablík provides a basic overview of LDL-C, how it might lead to atherosclerotic cardiovascular disease, and how this can ultimately cause a myocardial infarction. Vrablík covers current treatments for patients with high LDL-C, including statins, ezetimibe, and monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin Type 9.

Spotify | AppleAmazon MusicDownload MP3 (mp3, 32:29 mins)


Disclaimer: This independent medical education activity is provided by EMJ, and was supported by independent funding from Novartis Pharma AG, who have had no input into the content. This educational activity is intended for an audience of non-US healthcare professionals. These materials may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now